Part D Formulary Edits: CMS Focus On Covering All Labeled Uses Unwarranted, PCMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacy benefit managers express alarm that CMS is shifting on its definition of a medically-accepted indication for Medicare drug coverage.